Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs

por Rubio-Terrés, Carlos, Bernad Pineda, Miguel, Herrero, Marta, Nieto, Carlos, Rubio-Rodríguez, Darío
Publicado 2020

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

por Casado, Enrique, Rosas, José, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío, Boolell, Mitra, Arístegui, Ignacio
Publicado 2023

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

por Rubio-Terrés, Carlos, Graefenhain de Codes, Ruth, Rubio-Rodríguez, Darío, Evers, Thomas, Grau Cerrato, Santiago
Publicado 2016

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

por Isla, Dolores, De Castro, Javier, Juan, Oscar, Grau, Santiago, Orofino, Javier, Gordo, Rocío, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío
Publicado 2016

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

por Sánchez-Cenizo, Laura, Aller, Javier, Martínez-Sesmero, José Manuel, Mir, Nuria, Peral, Carmen, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos
Publicado 2019

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain

por Ginestal, Ricardo, Rubio-Terrés, Carlos, Morán, Olga Durán, Rubio-Rodríguez, Darío, Los Santos, Heidi De, Ordoñez, Cristina, Sánchez-Magro, Isabel
Publicado 2023

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain

por Casado, Luis Felipe, Burgos, Amparo, González-Haba, Eva, Loscertales, Javier, Krivasi, Tania, Orofino, Javier, Rubio-Terres, Carlos, Rubio-Rodríguez, Darío
Publicado 2016

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell T...

por Grau, Santiago, Solano, Carlos, García-Vidal, Carol, Jarque, Isidro, Barrueta, Jon A., Peral, Carmen, Rodríguez, Irene, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos
Publicado 2015

Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain

por Rubio-Terrés, Carlos, Aguado, José María, Almirante, Benito, Cobo, Javier, Grau, Santiago, Salavert, Miguel, González Antona Sánchez, Elena, López Gutiérrez, Cristina, Rubio-Rodríguez, Darío
Publicado 2019

Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la prevención del ictus en pacientes con fibrilación auricular no valvular en España

por Escolar-Albaladejo, Ginés, Barón-Esquivias, Gonzalo, Zamorano, José Luis, Betegón-Nicolás, Lourdes, Canal-Fontcuberta, Cristina, de Salas-Cansado, Marina, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos
Publicado 2016

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in...

por Grau, Santiago, Azanza, Jose Ramon, Ruiz, Isabel, Vallejo, Carlos, Mensa, Josep, Maertens, Johan, Heinz, Werner J, Barrueta, Jon Andoni, Peral, Carmen, Mesa, Francisco Jesús, Barrado, Miguel, Charbonneau, Claudie, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos
Publicado 2016